Why Neuronetics, Inc.’s (STIM) Stock Is Up 38.01%
As of Tuesday, August 11, Neuronetics, Inc.’s STIM share price has surged by 38.01%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. has a strategic collaboration with ANT Neuro to expand the capabilities of the NeuroStar advanced therapy system with advanced image-guided navigation technology. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Commentary & Analysis
What You Need to Know About Neuronetics, Inc.'s Q3 Earnings
Neuronetics, Inc.'s fiscal Q3 earnings report was released on Tuesday, August 11. Let's dive in to see if (STIM) missed or beat analyst's expectations.Jenna Brashear
Why Neuronetics, Inc.’s (STIM) Stock Is Up 35.25%
As of Tuesday, August 11, Neuronetics, Inc.’s STIM share price has surged by 35.25%, which has investors questioning if this is right time to sell.Omar Beirat
Why Neuronetics, Inc.’s (STIM) Stock Is Down 7.14%
As of Monday, August 10, Neuronetics, Inc.’s STIM share price has dipped by 7.14%, which has investors questioning if this is right time to buy.Michael Rose
Why Neuronetics, Inc.’s (STIM) Stock Is Down 11.76%
As of Monday, August 10, Neuronetics, Inc.’s STIM share price has dipped by 11.76%, which has investors questioning if this is right time to buy.Omar Beirat
Financial Summary
| Share Statistics | STIM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $235.4 | $407.7 | 29% |
|
| Shares Out (Mil) | 73.1 | 41.3 | 56% |
|
| Institutional Ownership | 56.2% | 81.4% | 38% |
|
| Float (Mil) | 34.9 | 34.9 | 39% |
|
| Beta | 1.12 | 0.88 | 67% |
|
| Avg Daily Volume (000s) | 4,964 | 412 | 92% |
|
| Price Change (52-week) |
(8.3%) | 64.8% | 38% |
|
| Growth | STIM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 24.8% | 11.8% | 86% |
|
| Net Income (5yr) | (7.2%) | (6.0%) | 32% |
|
| EPS (5yr) | 16.5% | 10.4% | 61 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 16.6% | (16.2%) | 76% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.110) | ($0.470) | ($0.340) | |
| Month Ago EPS | ($0.113) | ($0.465) | ($0.338) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 2 | |
| Three Months Ago EPS | ($0.113) | ($0.463) | ($0.337) | |
| Year/Year Chg | 134.0% | (20.5%) | (52.6%) | |
| Financials | STIM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $155 | $119 | 30% |
|
| Net Income (TTM) (Mil) | ($30) | ($9) | 20% |
|
| EPS (TTM) | ($0.437) | ($0.400) | 28% |
|
| Operating Cash Flow (TTM) (Mil) | ($10) | ($3) | 20% |
|
| Net Cash Flow (TTM) (Mil) | $8 | $1 | 54% |
|
| Long-Term Debt (Q1) (Mil) | $81 | $21 | 43% |
|
| Enterprise Value (Q1) (Mil) | $311 | $427 | 30% |
|
| Valuation | STIM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 13.43 | 3.06 | 93% |
|
| P/E | na | 27.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.7 | na |
|
| Ratios | STIM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 49.4% | 58.9% | 61% |
|
| Net Margin | (19.6%) | (6.9%) | 17% |
|
| ROA | (22.9%) | (12.7%) | 19% |
|
| ROE | (135.3%) | (13.1%) | 7% |
|
| Liabilities to Assets | 83.5% | 46.0% | 77% |
|
| F-Score | 4 | 4 | 34% |
|
Neuronetics, Inc. did not pass any screens on 8/20/2026.
